Ariad Prepares For Early Launch Of CML Drug Ponatinib

After filing a rolling submission for accelerated approval for wholly-owned Bcr-Abl inhibitor ponatinib in late July, Ariad plans to build a full commercial operation in the U.S. by the end of October.